SEA Antagonizes the Imatinib-Meditated Inhibitory Effects on T Cell Activation via the TCR Signaling Pathway
Figure 1
The cell proliferation and IL-2 production of Jurkat cells and PBMCs following TCR stimulation. (Control) Untreated Jurkat cells or PBMCs. (SEA) Cells were pretreated with SEA (20 ng/mL). (IM) Cells were pretreated with 40 nM imatinib. (SEA + IM) Cells were pretreated with SEA (20 ng/mL) for 24 h followed by 40 nM imatinib treatment for 15 min. Each group was stimulated with anti-CD3/CD28 coated beads at a cell : bead ratio of 5 : 1 for 24 h. Cell proliferation was assayed with the CCK-8 kit (a) and (b). The IL-2 level was assayed using a human IL-2 ELISA kit (c) and (d). The mean value and standard deviation of 3 independent experiments are shown.
